Company news
Oryzon Genomics SA news in 2021
Oryzon Genomics SA's news releases, calls and decks from 2021, newest first.
ORYZON to Present New Clinical Data and Corporate Updates at International Conferences in November and December
November 9, 2021
ORYZON Reports Results and Corporate Update for Quarter Ended September 30, 2021
October 28, 2021
ORYZON enrolls first patient in the US in PORTICO, a Phase IIb clinical trial with vafidemstat in Borderline Personality Disorder
October 18, 2021
ORYZON to Present New Clinical Data and Corporate Updates at International Conferences in September and October
September 22, 2021
Oryzon Announces $1 Million Grant From Kabuki Syndrome Philanthropists to Support a Precision Medicine Phase I/II Trial With Vafidemstat
September 21, 2021
ORYZON Reports Results and Corporate Update for First Half Ended June 30, 2021
July 29, 2021
ORYZON Presents Safety and Efficacy Data of Vafidemstat From the Phase II ESCAPE Trial in Severe COVID-19 Patients at ECCMID-2021
July 9, 2021
ORYZON announces FDA approval of IND for PORTICO, a Phase IIb trial with vafidemstat in Borderline Personality Disorder
June 15, 2021
ORYZON Reports Results and Corporate Update for Quarter Ended March 31, 2021
May 7, 2021
ORYZON Starts Preclinical Collaboration on Autism with the Seaver Autism Center at Mount Sinai
April 6, 2021
ORYZON Enrolls First Patient in PORTICO, a Phase IIb Clinical Trial With Vafidemstat in Borderline Personality Disorder
March 29, 2021
ORYZON Publishes Vafidemstat First-in-Human Clinical Trial Manuscript in CNS Drugs Journal
March 24, 2021
ORYZON Presents vafidemstat 12-month Clinical Data From its Phase IIa Clinical Trials ETHERAL and REIMAGINE-AD in Alzheimer’s at the Virtual AD/PD-2021 Conference
March 9, 2021
ORYZON Reports Results and Corporate Update for 4th Quarter and Year Ended December 31, 2020
February 23, 2021
ORYZON to Present a Corporate Update and to Hold Multiple Virtual Corporate Activities in January 2021
January 4, 2021